These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 27161301)

  • 21. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes.
    Buscemi S; Re A; Batsis JA; Arnone M; Mattina A; Cerasola G; Verga S
    Diabet Med; 2010 Aug; 27(8):872-8. PubMed ID: 20653743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential manipulation of endothelial progenitor cells in diabetes and its complications.
    Fadini GP; Avogaro A
    Diabetes Obes Metab; 2010 Jul; 12(7):570-83. PubMed ID: 20590732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. To the Future: The Role of Exosome-Derived microRNAs as Markers, Mediators, and Therapies for Endothelial Dysfunction in Type 2 Diabetes Mellitus.
    Fluitt MB; Mohit N; Gambhir KK; Nunlee-Bland G
    J Diabetes Res; 2022; 2022():5126968. PubMed ID: 35237694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes.
    Prattichizzo F; Giuliani A; Ceka A; Rippo MR; Bonfigli AR; Testa R; Procopio AD; Olivieri F
    Clin Epigenetics; 2015; 7(1):56. PubMed ID: 26015812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired signalling pathways mediated by extracellular vesicles in diabesity.
    Sáez T; Toledo F; Sobrevia L
    Mol Aspects Med; 2019 Apr; 66():13-20. PubMed ID: 30610887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications.
    Domingueti CP; Dusse LM; Carvalho Md; de Sousa LP; Gomes KB; Fernandes AP
    J Diabetes Complications; 2016; 30(4):738-45. PubMed ID: 26781070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extracellular vesicle microRNA transfer in cardiovascular disease.
    Das S; Halushka MK
    Cardiovasc Pathol; 2015; 24(4):199-206. PubMed ID: 25958013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy.
    Zhang Y; Sun X; Icli B; Feinberg MW
    Endocr Rev; 2017 Apr; 38(2):145-168. PubMed ID: 28323921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools.
    Prattichizzo F; Bonafè M; Ceka A; Giuliani A; Rippo MR; Re M; Antonicelli R; Procopio AD; Olivieri F
    Curr Drug Targets; 2016; 17(4):388-97. PubMed ID: 26240055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.
    Dandona P; Aljada A
    J Diabetes Complications; 2004; 18(2):91-102. PubMed ID: 15120703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammageing and metaflammation: The yin and yang of type 2 diabetes.
    Prattichizzo F; De Nigris V; Spiga R; Mancuso E; La Sala L; Antonicelli R; Testa R; Procopio AD; Olivieri F; Ceriello A
    Ageing Res Rev; 2018 Jan; 41():1-17. PubMed ID: 29081381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to Buscemi S et al. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes.
    Zaccardi F; Pitocco D; Caputo S; Ghirlanda G
    Diabet Med; 2011 Jan; 28(1):126; author reply 127-8. PubMed ID: 21166858
    [No Abstract]   [Full Text] [Related]  

  • 35. Insulin resistance, diabetes, and cardiovascular risk.
    Paneni F; Costantino S; Cosentino F
    Curr Atheroscler Rep; 2014 Jul; 16(7):419. PubMed ID: 24781596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic regulation in diabetic vascular complications.
    Jin J; Wang X; Zhi X; Meng D
    J Mol Endocrinol; 2019 Nov; 63(4):R103-R115. PubMed ID: 31600719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control.
    Santovito D; De Nardis V; Marcantonio P; Mandolini C; Paganelli C; Vitale E; Buttitta F; Bucci M; Mezzetti A; Consoli A; Cipollone F
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1681-5. PubMed ID: 24937531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-126 as a Therapeutic Agent for Diabetes Mellitus.
    Pishavar E; Behravan J
    Curr Pharm Des; 2017; 23(22):3309-3314. PubMed ID: 28440196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The endothelial dysfunction in diabetes mellitus.
    Pănuş C; Moţa M; Vladu D; Vanghelie L; Răducanu CL
    Rom J Intern Med; 2003; 41(1):27-33. PubMed ID: 15529582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.